BioNTech-Genentech cancer vax records more deaths than control in scrapped ph. 2 test
BioNTech and Genentech's mRNA cancer vaccine trial has been terminated after more deaths were recorded in the treatment group.
Evidence dossier
Intelligence passport
Measured timeline
- Detected The first matching coverage entered the Archynetys cluster.
- Latest coverage observed Most recent article currently attached to this story cluster.
- Peak measured velocity The recorded velocity reached 3.
- Evidence threshold reached The story had enough independent coverage for an explanatory brief.
Source diversity sample: Seeking Alpha · Yahoo Finance · Bloomberg.com · Reuters · Fierce Biotech.
How this dossier is built: methodology · AI policy · corrections.
Coverage (5)
- Arcturus, Moderna down on BioNTech trial setback (ARCT:NASDAQ) Seeking Alpha · 1d ago
- BioNTech to terminate mid-stage trial of mRNA cancer vaccine Yahoo Finance · 1d ago
- BioNTech, Roche Scrap Cancer Vaccine Trial in Blow to Field Bloomberg.com · 1d ago
- BioNTech halts mRNA colorectal cancer vaccine trial after safety review Reuters · 1d ago
- BioNTech-Genentech cancer vax records more deaths than control in scrapped ph. 2 test Fierce Biotech · 1d ago
Where it stands
The mRNA cancer vaccine developed by BioNTech and Genentech has been discontinued. The trial was halted after more deaths were recorded in the treatment group than in the control group. The trial's termination is a setback for the biotech industry, with BioNTech and Roche's joint effort ending abruptly.
The trial's termination was announced by BioNTech and Roche, with Reuters and Fierce Biotech specifying that the phase 2 trial was halted after a safety review. The trial involved an mRNA colorectal cancer vaccine. The trial's termination has affected the stock prices of other biotech companies, with Arcturus and Moderna experiencing declines.
The trial's termination raises questions about the safety and efficacy of mRNA cancer vaccines. The exact cause of the deaths and the specific safety concerns have not been detailed. The trial's termination is a significant setback for the biotech industry, which has been investing heavily in mRNA technology.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 1h ago.
Answered
What was the purpose of the BioNTech-Genentech cancer vaccine trial?
The trial was a phase 2 test of an mRNA colorectal cancer vaccine.
Why was the BioNTech-Genentech cancer vaccine trial terminated?
The trial was terminated after more deaths were recorded in the treatment group than in the control group.
How has the trial's termination affected the biotech industry?
The trial's termination has affected the stock prices of other biotech companies, with Arcturus and Moderna experiencing declines.
The coverage curve
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
Topics
Related trends
SINGLE-AF: DOAC Therapy vs. No Anticoagulation in AFib Patients at Intermediate Risk For Stroke
A major clinical trial has found that oral anticoagulants benefit atrial fibrillation patients at intermediate stroke risk.
In autopsy of failed heart disease study, AstraZeneca raises broader questions about silencer drugs
AstraZeneca and Ionis' failed heart disease drug trial raises questions about the future of RNA drugs
Cell therapy substantially reduces severe rheumatoid arthritis in first clinical trial
A clinical trial has shown that cell therapy can put severe rheumatoid arthritis into remission, offering new hope to patients.
Cancer is quantum: Studies show cancer cells may occupy limited, shared states like quantized energy levels
Recent studies suggest cancer cells may behave like quantum systems, occupying limited, shared states.
Arthritis drug may help regrow up to 80% of hair in alopecia areata
A drug used to treat arthritis is showing promise in treating alopecia areata, a condition that causes hair loss.
U.S. court orders Guardant to pay $245 million in DNA sequencing patent dispute
A $245 million patent dispute verdict has investors watching Guardant Health's next moves.
Open prediction lab
Can you beat the machine?
Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.
📬 The daily trend digest
The world's top trends, once a day. No spam, one-click unsubscribe.